Pressure BioSciences (OTCQB: PBIO),
a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food & beverage industries, has announced its strategic plan and goals for the second half of 2021. The company is calling the strong first half of 2021 a launch pad as it looks to an even stronger second half and a growth trajectory built on the success of multiple platform technologies. According to the announcement, the company has identified nine areas that have performed well so far this year and that it expects will continue to see excellent progress; the company identified goals for each area. Those areas are strengthen financial position; revenue and operating income; uplist to NASDAQ or NYSE; the acquisition of an eco-friendly agrochem company; expansion of intellectual property estate; its partnership with The Ohio State University; its proprietary Ultra Shear Technology (“UST”) platform; its Barofold platform; and its Pressure Cycling Technology (“PCT”) platform. “We have enjoyed a very exciting and successful first half 2021,” said Pressure BioSciences president and CEO Richard T. Schumacher in the press release. “As strong as this first half was, we believe the second half 2021 will be even stronger, in both financial and operational results. We are specifically excited about our key goals to close on the agrochem asset purchase, to completely clean up our balance sheet (as we convert debt to equity), to commercially release our UST-based nanoemulsions technology platform, and to complete our up-list, all by the end of 2021. These are very exciting times for all stakeholders in PBIO.”
To view the full press release, visit
https://ibn.fm/lA8MS
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) (“PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). The company’s primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of the company’s pressure-based technologies in the following areas: (1) the use of PBIO’s recently acquired, patented technology from BaroFold Inc. to allow entry into the biopharma contract services sector and (2) the use of PBIO’s recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to prepare higher-quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information about the company, visit
www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at
http://ibn.fm/PBIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.